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Introduction
Cardiac autonomic nervous dysfunction (CAND) is a frequent 
chronic complication of diabetes with potentially life-threaten-
ing effects such as silent myocardial ischemia and infarction, 
arrhythmia, sudden death, perioperative cardiovascular instabil-
ity, orthostatic hypotension, and cardiomyopathy (1–3). CAND 
is caused by the impairment of the autonomic nerve fibers 
regulating heart rate, myocardial contractility, cardiac elec-
trophysiology, and blood vessel constriction and dilatation (2). 
Hyperglycemia is the leading cause of this pathogenic process 
(4, 5). Because the clinical signs associated with CAND do not 
generally occur until late in the disease process and reversal of 
cardiovascular denervation is thought to be possible in the early 
stages of the disease (1, 3), screening tests are useful for the 
early detection of CAND.
Prediabetes is a continuum between normoglycemia and dia-
betes mellitus consisting of impaired fasting glucose (IFG) and/
or impaired glucose tolerance (IGT) and indicates an increased 
risk for cardiovascular diseases and the future development of 
type 2 diabetes mellitus (T2DM) (6). While patients with IFG and 
IGT both suffer from insulin resistance and deficiencies in insu-
lin secretion, the two conditions show some differences such as 
those in associated cardiovascular risk (7, 8). There is a strong 
correlation between cardiovascular events and IGT, whereas 
this relation is less clear in IFG (8). Studies investigating CAND 
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and prediabetes show conflicting results, particularly in terms of 
the relation between CAND and isolated IFG. It has been report-
ed that altered cardiac autonomic function is present in both IGT 
and diabetic subjects but not in patients with IFG (9). However, in 
the KORA S4 survey, the prevalence of CAND increased not only 
in individuals with T2DM and IGT but also in a lesser degree in 
those with isolated IFG (10).
Heart rate variability (HRV) and heart rate turbulence (HRT) 
are dependable Holter–electrocardiogram (ECG) parameters 
that indicate cardiac autonomic function (11, 12). The most com-
monly used methods for the diagnosis of CAND are based on 
HRV assessment (the physiological variation in the time interval 
between heartbeats) and enable the independent measurement 
of the parasympathetic and sympathetic components of the au-
tonomic nervous system (11). Another technique for evaluating 
CAND is the HRT, a reliable index of baroreceptor sensitivity, 
referring to variations in the sinus rhythm cycle length follow-
ing isolated premature ventricular beats (PVBs) (12). A decrease 
in HRV is the first finding of CAND (13). Similarly, HRT has been 
found to be disturbed in patients with CAND (14). 
This is the first study in the literature that aims to examine 
whether there is a relation between isolated IFG and cardiac au-
tonomic function using both HRV and HRT parameters. 
Methods
This observational, prospective, cross-sectional study exam-
ined 400 consecutive subjects who underwent an oral glucose 
tolerance test (OGTT) in the endocrinology outpatient department 
and were referred to the cardiology outpatient department for 
Holter–ECG assessments. The exclusion criteria were as follows: 
non-sinus rhythm, known T2DM, the use of any antidiabetic medi-
cation, history of coronary artery disease defined as a stenosis 
of more than 50% in at least one epicardial coronary artery in a 
past coronary angiography, acute coronary syndrome or a previ-
ous myocardial infarction, typical stable angina pectoris, cardio-
myopathies, heart failure (left ventricular ejection fraction <50%), 
severe valvular disease, hyperthyroidism, hypothyroidism, ven-
tricular tachycardia on Holter–ECG, and use of medicine, includ-
ing beta blockers, non-dihydropyridine calcium channel blockers, 
or antiarrhythmic drugs that may affect HRV and HRT indices.
The study was approved by the Local Ethics Committee and 
was performed in accordance with the Helsinki Declaration. All 
subjects gave informed consent prior to enrollment. 
A total of 481 individuals underwent a 24-h Holter recording 
to obtain HRV and HRT parameters between January 2013 and 
June 2014. Eighty-one subjects were excluded because of the 
absence of PVBs needed for HRT analysis on the Holter record-
ing. A total of 400 subjects were enrolled in the study.
The study population was divided into three groups accord-
ing to the results of the 75-g OGTT using American Diabetes As-
sociation criteria (6). The control group (Group I) included 193 
subjects with a fasting plasma glucose (FPG) of less than 100 
mg/dL and normal glucose tolerance (a 2-h OGTT glucose level 
below 140 mg/dL). The isolated IFG group (Group II) included 134 
patients with an FPG of 100–125 mg/dL and a 2-h OGTT glucose 
level below 140 mg/dL. Group III included 73 patients with either 
isolated IGT (FPG level below 100 mg/dL and a 2-h OGTT glu-
cose level between 140 and 200 mg/dL), both IFG and IGT (FPG 
level between 100 and 125 mg/dL and a 2-h OGTT glucose level 
between 140 and 200 mg/dL), or newly diagnosed T2DM (a 2-h 
OGTT glucose level above 200 mg/dL).
Holter–ECG recordings were acquired using three-channel 
digital recorders (Cardioscan Premier Version 12, DM Systems Co., 
Ltd. Beijing, China). Recordings lasting more than 20 h and of suffi-
cient quality for evaluation were analyzed. A physician completely 
blind to the study assessed the Holter–ECG records. Before analy-
sis, data were manually reviewed to check all complexes marked 
as true PVBs. HRV parameters included the standard deviation of 
the normal-to-normal (NN) interval (SDNN), the standard deviation 
of the average NN interval (SDANN) calculated over 5-min periods, 
the mean of the 5-min standard deviation of the NN interval (SDNN 
index) calculated over 24 h, the square root of the mean squared 
differences of successive NN intervals (RMSSD), and the division 
of the number of interval differences of successive NN intervals of 
more than 50 ms by the total number of NN intervals (pNN50). All 
analysis were made according to the standards determined by the 
Task Force of the European Society of Cardiology and the North 
American Society of Pacing and Electrophysiology (11).
HRT is the fluctuation in the sinus rhythm cycle length fol-
lowing isolated PVBs. After an initial acceleration, the sinus rate 
decelerates after a PVB. There are two components of HRT: tur-
bulence onset (TO) and turbulence slope (TS). A transient vagal 
inhibition triggers the mentioned initial acceleration in the heart 
rate as a reaction to the missed baroreflex afferent input due to 
hemodynamically ineffective ventricular contraction. The suc-
cessive deceleration in heart rate is caused by a sympathetical-
ly mediated overshoot of blood pressure through vagal recruit-
ment (15). After manual review of the Holter–ECG recordings, TO 
and TS were calculated as stated by Bauer et al. (12). A negative 
value of TO signifies early sinus acceleration and is considered 
normal, while a TS value over 2.5 ms/R-R interval indicates nor-
mal expected late deceleration (12). HRT values are generally 
classified into three categories: HRT category 0 indicating nor-
mal TO and TS, HRT category 1 indicating an abnormal TO or TS, 
and HRT category 2 indicating abnormal TO and TS (12).
Statistics
Data analysis was performed using the Statistical Package 
for the Social Sciences (SPSS) for Windows, version 11.5 (SPSS 
Inc., Chicago, IL, United States). The Kolmogorov–Smirnov test 
was used to determine whether continuous variable distribu-
tions were normal. Categorical variables were presented as 
the number of cases plus percentage and continuous variables 
as mean±standard deviation (SD) or median and 25/75% inter-
quartile ranges, where applicable. The chi-square test was used 
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for inter-group comparisons. Continuous variables were com-
pared between Groups I, II, and III using the one-way analysis 
of variance (ANOVA) or Kruskal–Wallis H tests as appropriate. 
The Mann–Whitney U test was used to compare continuous 
variables in terms of hypertension, gender, and smoking status. 
The correlation between Holter findings and FPG was analyzed 
using the Spearman’s test. Multiple linear regression analysis 
was used to determine the predictor(s) with the greatest effect 
on the HRV and HRT parameters after adjustment for all pos-
sible confounding factors. Variables with a p value of <0.10 in the 
univariable test as well as all variables of known clinical impor-
tance were accepted as a candidate for the multivariable model. 
Standardized coefficient of regression and levels of significance 
for each independent variable were also calculated. Logarithmic 
transformation was used for SDNN, SDNN index, SDANN, RMS-
SD, pNN50, TO, and TS in regression analysis as data were not 
normally distributed. All tests of significance were two-tailed. 
Statistical significance was defined as p<0.05.
Results
Baseline characteristics and clinical, laboratory, and echo-
cardiographic fi ndings are presented in Table 1. Although the 
ratio of patients with hypertension was higher in Groups II and 
III, this difference was not significant. As expected, median FPG 
levels were significantly higher in Groups II and III than in the 
control group and higher in Group III than in Group II (p<0.001, 
p<0.001, and p<0.001, respectively). 
Holter data are given in Table 2. The duration of Holter–ECG 
recordings and mean R-R intervals were similar in all groups. 
HRV and HRT parameters were significantly different between 
Groups I and II (SDNN: p=0.013, SDNN index: p=0.018, SDANN: 
p=0.032, RMSSD: p=0.012, pNN50: p=0.005, TO: p<0.001, TS: 
p<0.001); Groups I and III (SDNN: p<0.001, SDNN index: p<0.001, 
SDANN: p<0.001, RMSSD: p<0.001, pNN50: p<0.001, TO: p<0.001, 
TS: p<0.001); Groups II and III (SDNN: p=0.017, SDNN index: 
p=0.032, SDANN: p=0.010, RMSSD: p=0.005, pNN50: p=0.018, 
TO: p<0.001, TS: p=0.001); and among all groups (Table 2). SDNN, 
SDNN index, SDANN, RMSSD, pNN50, and TS gradually de-
creased from Group I to Group III, while TO and HRT category 
increased (Table 2). HRV and HRT measurements according to 
gender, hypertension, and smoking status are presented in Table 
3. SDNN (p<0.001), SDNN index (p=0.001), SDANN (p<0.001), TO 
(p=0.005), and TS (p<0.001) were significantly different in pa-
tients with hypertension.
Correlation analyses revealed that FPG was significantly as-
sociated with SDNN (r=–0.220, p<0.001), SDNN index (r=–0.192, 
p<0.001), SDANN (r=–0.207, p<0.001), RMSSD (r=–0.228, p<0.001), 
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Table 1. Baseline characteristics and echocardiographic and laboratory findings
Variables Group I (n=193) Group II (n=134) Group III (n=73) P
Age, years 54 (42/68) 58 (48/71) 56 (50.5/63) 0.126
Gender, male/female, numbers (%) 84/109 (43.5/56.5) 55/79 (41/59) 32/41 (43.8/56.2) 0.886
Current smoking, numbers (%) 46 (23.8) 31 (23.1) 22 (30.1) 0.494
Hypertension, numbers (%) 57 (29.5) 47 (35.1) 29 (39.7) 0.249
Body mass index, kg/m2 28.4 (26.1/31.6) 28.7 (25.7/32.1) 29 (25.4/31.6) 0.912
FPG, mg/dL 89 (83/93) 109 (104/116) 174 (150.5/197) <0.001
HbA1c*, % 5.1±0.3 5.9±0.2 6.9±0.9 <0.001
Total cholesterol, mg/dL 189.1 (159.5/226.4) 194.6 (163.6/221) 200.7 (174/228.3) 0.251
HDL cholesterol, mg/dL 46 (39/54) 45.5 (39.3/52) 44 (38.5/53.5) 0.642
LDL cholesterol, mg/dL 114 (92/146) 120 (96/146) 126 (101/149) 0.263
Triglycerides, mg/dL 116 (90/158) 122.5 (88/178) 134 (95.5/187.5) 0.159
Systolic blood pressure, mm Hg 120 (112.5/132.5) 120 (110/140) 120 (110/130) 0.432
Diastolic blood pressure, mm Hg 80 (70/80) 75 (70/80) 80 (70/80) 0.502
Mean heart rate*, beats/min 75.2±10.8 75.4±10.9 73.8±10.1 0.545
Left ventricular diastolic diameter, mm 46 (42/48) 46 (40/49) 46 (43/49) 0.444
Left ventricular systolic diameter, mm 29 (26/32) 29 (26/33) 29 (27/32) 0.658
Interventricular septum thickness, mm 11 (10/12) 11 (10/12) 11 (10/12) 0.961
Posterior wall thickness, mm 10 (9/12) 10 (9/11) 10 (9/11.8) 0.878
Ejection fraction, % 65 (60/67) 65 (60/67) 64 (59/67) 0.175
Left atrial diameter, mm 35 (31/38) 35 (31/38) 34 (32/38) 0.738
Group I - subjects with FPG <100 mg/dL and normal glucose tolerance test; Group II - patients with isolated IFG; Group III - patients with isolated IGT/both IFG and IGT/newly diagnosed 
T2DM; FPG - fasting plasma glucose; IFG - impaired fasting glucose; IGT - impaired glucose tolerance. Data presented as median (25/75% interquartile range). *Data presented as 
mean±standard deviation. Kruskal–Wallis or one-way ANOVA test was used for continuous variables. Chi-square test was performed for the comparison of categorical variables
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pNN50 (r=–0.226, p<0.001), TO (r=0.354, p<0.001), and TS (r=–0.331, 
p<0.001). TO had the strongest power among all HRV and HRT pa-
rameters regarding correlation with FPG level (Table 4). 
Multiple linear regression analysis was performed to determine 
the independent predictors of HRV and HRT measures. Age had an 
independent relation with SDNN, SDNN index, SDANN, TO, and TS. 
The presence of hypertension was another independent predictor 
of SDANN and TS. In addition, FPG level was an independent deter-
minant of all examined HRV and HRT parameters (Table 5).
Discussion
According to our knowledge, this is the first study in the lit-
erature investigating the relation between HRT and prediabe-
Table 2. Comparison of 24-h Holter electrocardiographic findings, heart rate variability, and heart rate turbulence parameters
Variables Group I  Group II  Group III  P
Recording time, h 23.1 (22.5/23.6) 23.3 (22.6/23.7) 23.1 (22.6/23.5) 0.128
Mean RR interval, ms 797.9 (722.6/908.6) 799.6 (731.3/872.3) 779.1 (728.4/874.1) 0.649
Heart rate variability parameters
SDNN, ms 125 (100.5/153) 117 (94.5/134.5) 102 (84/119) <0.001
SDNN index, ms 50 (41/62) 44 (36/58) 42 (33/51) <0.001
SDANN, ms 113 (89.5/137.5) 102.5 (83.8/123.5) 90 (72/109.5) <0.001
RMSSD, ms 29 (21/37) 24 (19/33) 22 (17/25) <0.001
pNN50, % 7 (2/12.5) 3.5 (1.8/9) 2 (1.1/4) <0.001
Heart rate turbulence parameters
Turbulence onset, % -1.879 (-3.843/-0.46) -0.610 (-2.033/0) -0.003 (-0.008/0.003) <0.001
Turbulence slope, ms/RR 7.8 (3.4/13) 4.3 (2.5/8.5) 3 (2.1/4.4) <0.001
Heart rate turbulence category
0, numbers (%) 141 (73.1) 81 (60.4) 39 (53.4)
1, numbers (%) 42 (21.8) 41 (30.6) 20 (27.4) 0.001
2, numbers (%) 10 (5.2) 12 (9) 14 (19.2)
Group I - subjects with FPG <100 mg/dL and normal glucose tolerance test; Group II - patients with isolated IFG; Group III - patients with isolated IGT/both IFG and IGT/newly diagnosed 
T2DM; IGT - impaired glucose tolerance; IFG - impaired fasting glucose; FPG - fasting plasma glucose; pNN50 - the proportion of adjacent RR intervals differing by >50 ms in the 24-h 
recording; RMSSD - the square root of the mean squared differences of successive normal-to-normal intervals; SDANN - the standard deviation of the average normal-to-normal 
intervals calculated over the 5-min period of the entire recording; SDNN - the standard deviation of all normal-to-normal intervals; SDNN index - the mean of the deviation of the 5-min 
normal-to-normal intervals over the entire recording. Data presented as median (25/75% interquartile range). The Kruskal–Wallis and chi-square tests were used
Table 3. Heart rate variability and heart rate turbulence measurements according to gender, hypertension, and smoking status
Variables SDNN SDNN index SDANN RMSDD pNN50 TO TS
Gender
 Female (n=229) 116 (96/141) 46 (38/56) 106 (84/128) 27 (19.5/34) 5 (2/11) -0.750 (-2.913/-0.001) 4.8 (2.8/11)
 Male (n=171) 118 (90/141) 49 (35/60) 102 (77/127) 24 (18/33) 4 (1.2/9) -0.867 (-2.637/-0.003) 4.7 (2.4/9.5)
 P 0.809 0.464 0.372 0.195 0.164 0.796 0.273
Hypertension
 No (n=267) 120 (98/150) 49 (39/60) 109 (89/132) 27 (19/34) 4.1 (2/11) -1.045 (-3.310/-0.003) 5.5 (2.9/12.4)
 Yes (n=133) 110 (87.5/132) 43 (35/52) 99 (72/119.5) 24 (17.5/33) 4 (1.1/8) -0.420 (-1.979/0.008) 3.9 (2.1/6.9)
 P <0.001 0.001 <0.001 0.259 0.099 0.005 <0.001
Smoking
 No (n=301) 117 (92/140.5) 46 (37/58) 105 (80.5/128) 27 (19/34) 4 (2/10) -0.967 (-2.836/-0.001) 4.8 (2.7/10.9)
 Yes (n=99) 119 (98/141) 49 (37/60) 103 (89/128) 24 (18/34) 3.8 (1.3/9) -0.500 (-2.807/-0.002) 4.7 (2.7/10.2)
 P 0.543 0.802 0.427 0.492 0.485 0.399 0.879
pNN50 - the proportion of adjacent RR intervals differing by >50 ms in the 24-h recording; rMSSD - the square root of the mean squared differences of successive normal-to-normal 
intervals; SDANN - the standard deviation of the average normal-to-normal intervals calculated over 5-min period of the entire recording; SDNN - the standard deviation of all normal-
to-normal intervals; SDNN index - the mean of the deviation of the 5-min normal-to-normal intervals over the entire recording; TO - turbulence onset; TS - turbulence slope. Data 
presented as median (25/75% interquartile range). Analyzed using the Mann–Whitney U test
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tes. In addition, our study clarifies the conflicting data regard-
ing CAND and IFG. The principal findings of this study were as 
follows: 1) Patients with isolated IFG were likely to have CAND; 
2) While time domain HRV parameters and TS decreased from 
Group I to Group III, TO and HRT category gradually increased; 
3) FPG level was significantly correlated with time domain HRV 
Table 4. Correlation coefficients and significance levels between both heart rate variability and also heart rate turbulence parameters with 
baseline characteristics, echocardiography, and laboratory measurements
Variables SDNN SDNN index SDANN rMSDD pNN50 TO TS
Age
 R -0.268** -0.300** -0.267** -0.079 -0.143** 0.238** -0.334**
 P <0.001 <0.001 <0.001 0.113 0.004 <0.001 <0.001
Body mass index
 R -0.064 -0.055 -0.047 0.032 0.044 0.079 0.039
 P 0.199 0.274 0.353 0.524 0.376 0.114 0.434
FPG
 R -0.220** -0.192** -0.207** -0.228** -0.226** 0.354** -0.331**
 P <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001
Systolic BP
 R -0.078 -0.088 -0.063 -0.021 -0.045 0.084 -0.062
 P 0.118 0.077 0.212 0.669 0.368 0.093 0.217
Diastolic BP
 R -0.086 -0.063 -0.079 -0.034 -0.028 0.030 -0.092
 P 0.087 0.211 0.113 0.493 0.580 0.547 0.067
HDL cholesterol
 R 0.095 0.048 0.093 0.027 0.025 -0.059 0.126*
 P 0.059 0.346 0.066 0.595 0.624 0.248 0.012
LDL cholesterol
 R 0 -0.035 0.020 -0.078 -0.100* 0.002 0.001
 P 0.993 0.483 0.690 0.121 0.046 0.972 0.989
Triglycerides
 R -0.096 -0.077 -0.077 -0.058 -0.036 -0.027 -0.121*
 P 0.057 0.127 0.126 0.253 0.482 0.596 0.017
LVEF
 R 0.112* 0.038 0.133** 0.070 0.080 -0.065 0.135**
 P 0.026 0.446 0.008 0.160 0.111 0.194 0.007
IVS thickness
 R -0.052 -0.011 -0.066 0.014 0.026 0.080 -0.048
 P 0.302 0.833 0.189 0.775 0.599 0.111 0.340
PW thickness
 R -0.071 -0.017 -0.094 0.009 0.027 0.085 -0.088
 P 0.156 0.741 0.060 0.850 0.589 0.091 0.080
Left atrial diameter
 R -0.049 0.002 -0.078 0.048 0.034 0.048 -0.151**
 P 0.332 0.975 0.118 0.336 0.501 0.341 0.003
BP - blood pressure; FPG - fasting plasma glucose; IVS - interventricular septum; LVEF - left ventricular ejection fraction; pNN50 - the proportion of adjacent RR intervals differing by 
>50 ms in the 24-h recording; R - coefficient of correlation; PW - posterior wall; rMSSD - the square root of the mean squared differences of successive normal-to-normal intervals; 
SDANN - the standard deviation of the average normal-to-normal intervals calculated over the 5-min period of the entire recording; SDNN - the standard deviation of all normal-to-
normal intervals; SDNN index - the mean of the deviation of the 5-min normal-to-normal intervals over the entire recording; TO - turbulence onset; TS - turbulence slope. Spearman’s 
test was used. *P<0.05; **P<0.01
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parameters, TO, and TS; and 4) FPG and age were significant 
independent predictors of almost all impaired HRV and HRT 
parameters. Accordingly, altered sympathovagal function as re-
vealed by impaired HRV and HRT was present in patients with 
isolated IFG and this influence was independently associated 
with the FPG level.
Prediabetes, a clinical condition standing on the continuum 
between a normal glycemic state and overt T2DM, is related with 
increased risk of the similar macrovascular and microvascular 
complications of overt diabetes (16). The overall prevalence of 
prediabetes was 36.5% among individuals older than 18 years in 
the National Health and Nutritional Examination Survey (17). Ac-
cording to the Turkish Diabetes Epidemiology Study II, which in-
cluded 26,499 adults aged ≥20 years (mean age 45.8±15.3 years), 
the prevalence of prediabetes was 30.8% in Turkey (isolated IFG: 
14.7%, isolated IGT: 7.9%, both IFG and IGT: 8.2%) (18). 
CAND is one of the most important microvascular compli-
cations because of its association with significantly increased 
cardiovascular morbidity and mortality (19, 20). Clinical symp-
toms generally occur late in the disease process (1). However, 
the first finding of CAND is a decrease in HRV, which is appar-
ent even at the subclinical stage (21). SDNN represents both the 
sympathetic and parasympathetic modulation of HRV, RMSSD, 
and the pNN50 parasympathetic system (11). As with HRV, HRT 
has also been determined to be applicable in the diagnosis of 
CAND (12). Two components of HRT, TO and TS, are critically 
vagal dependent and reflect the status of the parasympathetic 
system (22). 
Although the relation between CAND and IGT is well estab-
lished in several studies (23–26), previous studies have shown 
incompatible results with each other regarding the relation be-
tween CAND and isolated IFG. The FPG levels were classified 
as normal (<110 mg/dL, n=1779), IFG (110–125 mg/dL, n=56), and 
T2DM (≥126 mg/dL or receiving antidiabetic therapy, n=84) in the 
Framingham Heart Study (27). Although their IFG subjects had 
higher FPG criterion than our subjects (110 mg/dL vs. 100 mg/
dL), SDNN and low-frequency and high-frequency power were 
inversely associated with plasma glucose levels and those pa-
rameters were reduced in both the diabetic and the IFG groups. 
However, in the Framingham Heart Study, classification of pa-
tients into normal glucose tolerance, IFG, and T2DM groups by 
solely FPG without OGTT may cause confusion because pa-
tients with IFG may also have IGT or diabetes. Therefore, us-
ing such a method, it is impossible to determine isolated IFG. 
Wu et al. (9) reported that altered cardiac autonomic function, 
as examined by SDNN, 30/15 ratio, and frequency-domain HRV 
parameters, was present in both IGT and diabetic subjects, but 
was not different in patients with isolated IFG from those with 
normal glucose tolerance. As in Wu’s report, the Atherosclero-
sis Risk in Communities (ARIC) Study used a FPG level of <100 
mg/dL as its IFG criterion and showed that there was no dif-
ference in SDNN between those with IFG and normal glucose 
tolerance (28). However, similar to the Framingham Heart Study, 
the ARIC study could not examine the influence of IGT in IFG 
subjects. The current study may be considered more reliable 
because of our use of 2-h OGTT glucose levels for the deter-
mination of true isolated IFG patients. Additionally, the differ-
ence in results between the current study and that of Wu et 
al. (9) may be caused by glycemia differences between normal 
glucose tolerance and isolated IFG groups. While mean HbA1c 
Table 5. The results of multiple linear regression analysis for determining the best predictors that affect heart rate variability and heart rate 
turbulence parameters
Variables SDNN SDNN index SDANN rMSDD pNN50 TO TS
Age
 Beta (standardized) -0.206 -0.257 -0.181 – -0.106 0.245 -0.295
 P <0.001 <0.001 <0.001 – 0.034 <0.001 <0.001
Fasting plasma glucose
 Beta (standardized) -0.133 -0.152 -0.161 -0.214 -0.217 0.226 -0.257
 P 0.007 0.002 0.001 <0.001 <0.001 <0.001 <0.001
Presence of hypertension
 Beta (standardized) -0.098 -0.063 -0.134 – -0.035 0.057 -0.102
 P 0.050 0.220 0.007 – 0.487 0.256 0.032
Constant
 B 2107 1883 2040 1541 1351 0.748 1255
 P <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001
Adjusted R2 0.111 0.099 0.109 0.043 0.065 0.132 0.232
pNN50 - the proportion of adjacent RR intervals differing by >50 ms in the 24-h recording; rMSSD - the square root of the mean squared differences of successive normal-to-normal 
intervals; SDANN - the standard deviation of the average normal-to-normal intervals calculated over the 5-min period of the entire recording; SDNN - the standard deviation of all 
normal-to-normal intervals; SDNN index - the mean of the deviation of the 5-min normal-to-normal intervals over the entire recording; TO - turbulence onset; TS - turbulence slope. The 
independent predictors of SDNN, SDNN index, SDANN, rMSSD, pNN50, TO, and TS were identified by multiple linear regression analysis
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values were quite close between the normal glucose tolerance 
and isolated IFG groups (4.9%±0.5% vs. 5.1%±0.5%) in Wu et 
al.’s study (9), they were 5.1%±0.3% vs. 5.9%±0.2% in our study. 
Therefore, the IFG subjects in Wu et al.’s (9) study may be less 
hyperglycemic compared with our isolated IFG patients, which 
could result in a similarity in HRV parameters between the nor-
mal glucose tolerance and isolated IFG groups.
In the recent Kora S4 survey of 1202 participants (the num-
ber of individuals with normal glucose tolerance, isolated IFG, 
isolated IGT, both IFG and IGT, and newly diagnosed T2DM was 
565, 336, 72, 151, and 78, respectively), the prevalence of CAND 
increased in individuals with T2DM and IGT as well as in those 
with isolated IFG (10). Similarly, we observed that SDNN, SDNN 
index, SDANN, RMSSD, and pNN50 values were lower in the 
isolated IFG group than in the control group but higher than in 
the isolated IGT, both IFG and IGT, or newly diagnosed T2DM 
group. Different from the previous HRV studies, a novel finding 
of our study was the demonstration of the relation between 
disturbed HRT indices and prediabetes. We observed that TO 
and TS values and HRT category were impaired in patients with 
isolated IFG compared with the subjects with normal glucose 
tolerance, reflecting mainly parasympathetic CAND. In addition, 
correlation analysis revealed the continuous relation between 
FPG and HRV and HRT parameters. Our study also demonstrat-
ed that FPG was an independent determinant of almost all HRV 
and HRT parameters.
Although only parasympathetic involvement is expected in 
the early stages of CAND (4), disturbance in all studied HRV and 
HRT parameters indicates the impairment of both parasympa-
thetic and sympathetic limbs of the autonomic nervous system, 
even in an isolated IFG state. These findings support the fact that 
patients may have subclinical CAND that is more serious than is 
believed for several years before it becomes clinically apparent 
(29). Accordingly, because the progression of cardiovascular de-
nervation is partly reversible or can be slowed down in the early 
stages of the disease (30), screening for CAND may be recom-
mended for all prediabetic patients in addition to all newly diag-
nosed T2DM patients. Assessment of CAND is possible through 
a variety of methods, such as cardiovascular autonomic reflex 
tests, HRV, and imaging modalities (3). The criteria for diagnosis 
and staging are published elsewhere (31).
Study limitations
The first limitation of this study was the absence of Ewing’s 
cardiovascular autonomic reflex tests, which are the gold stan-
dard for the determination of CAND. However, studies compar-
ing Holter-based HRV analysis and cardiovascular autonomic 
reflex tests found a high correlation between both techniques. 
Additionally, frequency domain methods were not performed 
for HRV analysis. However, many time- and frequency-domain 
variables obtained over the 24-h period were found to be highly 
correlated with each other. 
Conclusion
Findings of this study revealed that HRT disturbance, consid-
ered a sign of sympathovagal imbalance, is already present in 
the prediabetic stage. Our study also verified recent data regard-
ing the existence of a relation between CAND and isolated IFG 
and demonstrated the independent relation between FPG and 
almost all HRV and HRT parameters. It seems important to be 
aware of CAND in all prediabetic patients, including those with 
isolated IFG. Because previous data suggests that the reversal of 
cardiovascular denervation may occur in the early stages of the 
disease; screening of all subgroups of prediabetic patients for 
CAND may be considered.
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